Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.02
+0.03013.04%
Post-market: 1.01-0.0100-0.98%19:45 EDT
Volume:1.02M
Turnover:962.26K
Market Cap:59.79M
PE:-3.57
High:1.02
Open:0.8800
Low:0.8100
Close:0.9899
Loading ...

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

Zacks
·
28 Mar

IceCure Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
28 Mar

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

IceCure Medical Sees 42% Growth in ProSense® Sales Amid Awaited FDA Decision

TIPRANKS
·
27 Mar

BRIEF-Icecure Medical FY Gross Margin 44%

Reuters
·
27 Mar

Icecure Medical FY 2024 GAAP EPS $(0.30) Misses $(0.29) Estimate, Sales $3.29M Miss $3.48M Estimate

Benzinga
·
27 Mar

Icecure Medical FY Gross Margin 44%

THOMSON REUTERS
·
27 Mar

Press Release: IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense(R) Cryoablation Sales in North America

Dow Jones
·
27 Mar

BRIEF-IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Reuters
·
24 Mar

IceCure Medical announces interim results from ICESECRET study

TIPRANKS
·
24 Mar

Icecure's Icesecret Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

THOMSON REUTERS
·
24 Mar

Icecure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

THOMSON REUTERS
·
21 Mar

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

PR Newswire
·
21 Mar

BUZZ-IceCure Medical falls after FDA delays decision on breast cancer treatment system

Reuters
·
21 Mar

IceCure Medical Expects FDA Decision on ProSense After Q1

MT Newswires Live
·
20 Mar

IceCure Medical in discussions with FDA on marketing request for ProSense

TIPRANKS
·
20 Mar

Icecure Reports Updated Timeline and Progress With FDA Regarding Marketing Authorization for Prosense® Cryoablation in Early-Stage Breast Cancer

THOMSON REUTERS
·
20 Mar

Icecure Medical : Expects to GET FDA's Marketing Authorization Decision for Prosense After Q1 of 2025

THOMSON REUTERS
·
20 Mar

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

PR Newswire
·
20 Mar

IceCure Gets Notice of Allowance from China's Intellectual Property Regulator

MT Newswires Live
·
17 Mar